Business
US Patent for Teverelix LA
US Patent for Teverelix LA.
About this update from Aura Renewable Acquisitions Plc
[{"type":"text","content":"\n Ardana PLC\n31 August 2006\n\n US PATENT GRANTED TO ARDANA FOR TEVERELIX LA\n\n\n\nEdinburgh, UK, 31 August 2006; Ardana (LSE: ARA), the pharmaceutical company\nfocused on improving human reproductive health, today announces that it has been\ngranted a US patent, number 7,098,305, covering the long acting formulation of\nits GnRH antagonist, Teverelix (Teverelix LA).\n\n\n\nThe patent is subject to a US patent term adjustment (i.e. extension), which\nmeans that it is not due to expire in the US until April 2023.\n\n\n\nThis patent forms part of Ardana's growing intellectual property portfolio\naround its research and development activities.\n\n\n\nTeverelix is Ardana's lead development compound and is in Phase II clinical\ntrials in two indications; prostate cancer and benign prostatic hyperplasia,\nwith Phase I studies ongoing in endometriosis.\n\n\n\n\n\nFor more information contact:\n\n\nArdana Financial Dynamics\nMaureen Lindsay (corporate/financial media relations)\nTel: + 44 (0) 131 226 8550 Julia Phillips/John Gilbert\n Tel: +44 (0)20 7831 3113\n\n\n\n\n\nAbout Ardana\n\nArdana plc is a pharmaceutical company focused on the discovery, development and\nmarketing of innovative products to improve human reproductive health, a $25.5\nbillion market.\n\n\n\nSince its foundation, Ardana has maintained a broad and balanced portfolio to\nmanage risk and actively pursues product and technology in-licensing and\noutlicensing to maintain a robust pipeline.\n\n\n\nArdana's four lead products are summarised below:\n\n\n\n • StriantTM SR, a testosterone replacement therapy that has been launched by\n Ardana through its own sales force in the UK and through marketing partners\n in certain European countries, as a treatment for men with hypogonadism;\n • Teverelix LA, in development for three initial indications (prostate\n cancer, BPH and endometriosis);\n • Testosterone Cream, a trans dermal testosterone delivery system in\n development for the treatment of male hypogonadism, in Phase II trials;\n • Invicorp, an injectable combination drug treatment for erectile\n dysfunction, for which Ardana has marketing and manufacturing rights in\n Europe.\n\n\n\nIn addition, Ardana has a strong portfolio of follow-on products in development.\n\nArdana is listed on the Main Market of the London Stock Exchange.\n\n\n\nFor further informa...